Exchange: NASDAQ·Updated 07:52 PM EDT
MTVA logo

MTVA MetaVia Inc.

$1.75
$0.09
(4.89%)
Today
Closed $1.75
$0.02
(1.14%)
After Hours
Mkt Cap$12.12M
Vol81,303.00

About MTVA

MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
66

Bullish Sentiment

How do you feel about MTVA?

Advertisement|Remove ads.